Search for drugs:
Typing the drug name to query
IDARUCIZUMAB
DIR Classification
Classification:Ambiguous
Severity Score:1.0
Description in Drug Labeling: View Full Labeling: SPL in DailyMed | PDF
- CLINICAL PHARMACOLOGY
- Pharmacodynamics
- Cardiac Electrophysiology
- Clinical trials with idarucizumab in healthy subjects measured heart rate and electrocardiogram (ECG) parameters (waveform morphology, P wave duration, and PR, QRS, QT, and QTc intervals). There were no clinically relevant abnormal findings related to ECG.
Postmarketing Surveillance
Contingency Table:
Current Drug
Other Drugs
QT Prolongation
0
24092
Other ADRs
0
38381587
Odds Ratio = N/A
Drug Property Information
ATC Code(s):
- V03AB37 - idarucizumab
- V03AB - Antidotes
- V03A - ALL OTHER THERAPEUTIC PRODUCTS
- V03 - ALL OTHER THERAPEUTIC PRODUCTS
- V - VARIOUS
Active Ingredient:IDARUCIZUMAB
Active Ingredient UNII:97RWB5S1U6
Drugbank ID:DB09264
PubChem Compound:N/ADIR Classification
CAS Number:
Dosage Form(s):injection
Route(s) Of Administrator:intravenous
Daily Dose:
Chemical Structure: 
SMILE Code:
Reference
N/A
Disclaimer:
The content of this database of QT prolongation is intended for educational and scientific research purposes only. It is not intended as a substitute for professional medical advice, diagnosis or treatment.
Any mention of commercial products is for clarification and not intended as endorsement.